Allergan: Why Goldman Sachs Sees Stock Climbing 24% to $275

Goldman Sachs says it’s time to Allergan ( AGN ). Analyst Jami Rubin and her team added the beaten down specialty drug maker to the firm’s Conviction List, arguing that the company is primed for growth with a best in class pipeline that features more than 70 “ unique assets featuring several first-in-class or best-in-class candidates.”